Liminatus Pharma (NASDAQ:LIMN) Cut to “Strong Sell” at Wall Street Zen

Wall Street Zen cut shares of Liminatus Pharma (NASDAQ:LIMN) to a strong sell rating in a research note published on Saturday morning.

Separately, Weiss Ratings upgraded shares of Liminatus Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Liminatus Pharma Trading Down 9.5%

NASDAQ:LIMN opened at $4.67 on Friday. Liminatus Pharma has a 12-month low of $4.61 and a 12-month high of $179.99. The firm has a market cap of $4.72 million, a PE ratio of -0.20 and a beta of 5.34. The stock has a fifty day moving average price of $5.82 and a 200 day moving average price of $11.34.

Liminatus Pharma (NASDAQ:LIMN) last posted its quarterly earnings results on Friday, August 14th. The company reported ($1.50) earnings per share for the quarter.

About Liminatus Pharma

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.